How to Move Forward After a Thumbs Down from FDA

Interview with Kevin Sidow, Former CEO and President of Moximed

In late 2016, I was able to sit down with Kevin Sidow. At the time, he was President & Chief Executive Officer for Moximed, and had been since 2008.

Prior to his time at Moximed, Kevin was President & CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.

Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.

Interview Highlights with Kevin Sidow

  • How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.
  • What makes the Atlas System different than other orthopedic knee implants.
  • How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.
  • How Kevin and his team responded when their device received an unfavorable response from an FDA panel.
  • Kevin’s approach to financing a medtech startup after raising nearly $100M to fund Moximed.
  • Kevin’s favorite business book, the CEO he most admires, and the advice he’d give to his 25-year-old self.
Guest
Download a copy of the interview transcript right here.
Share:
Twitter
Facebook
LinkedIn
Email

In late 2016, I was able to sit down with Kevin Sidow. At the time, he was President & Chief Executive Officer for Moximed, and had been since 2008.

Prior to his time at Moximed, Kevin was President & CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.

Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.

Interview Highlights with Kevin Sidow

  • How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.
  • What makes the Atlas System different than other orthopedic knee implants.
  • How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.
  • How Kevin and his team responded when their device received an unfavorable response from an FDA panel.
  • Kevin’s approach to financing a medtech startup after raising nearly $100M to fund Moximed.
  • Kevin’s favorite business book, the CEO he most admires, and the advice he’d give to his 25-year-old self.
Guest
Download a copy of the interview transcript right here.
Share:
Twitter
Facebook
LinkedIn
Email

You May Like These Articles

Premium

Crowdfunding and IPOs for Medtech Startups

Interview with Monogram Orthopedics CEO Benjamin Sexson

Benjamin Sexson is the President and CEO of Monogram Orthopedics. He is a mechanical engineer from Caltech and a CFA charterholder. At Monogram, Ben and his team are developing a fully autonomous robotic system for knee replacement surgery. In this interview, Ben talks about the importance of a good team and a liberating company culture as well as the importance of believing in what you’re doing and openly reassessing its validity regularly. He also elaborates on Monogram’s daring strategies for validating its technology and walks us through the pros and cons of crowdfunding and going public.

Premium

Mission-Driven Entrepreneurship

Interview with NEXT Life Sciences’ Founder L.R. Fox

In this interview, we pull back the curtain on L.R. Fox, the visionary founder of NEXT Life Sciences. With an ambitious mission to democratize family planning, Fox and his team are on the brink of launching their flagship product, Plan A— a groundbreaking male contraceptive. Fox shares invaluable lessons on fostering collaboration in a competitive space, understanding key stakeholders, and the art of raising capital. Whether you're an aspiring entrepreneur or simply curious about how innovation can drive societal change, this conversation offers key takeaways for all.

Premium

Medsider Mentors

Volume VI

In Medsider Mentors Volume VI, we’ve distilled key insights from founders and CEOs of some of the hottest medical device and health technology startups including LimFlow, Field Medical, Sinaptica, Spark Biomedical, InterShunt and many more.

View More Interviews
See the Playbooks

Join Medsider as a Free Subscriber

Subscribe to Medsider and get access to exclusive benefits for free. No spam, 100% privacy, and your email won’t be shared.